 |
|
|
|
April 2000 Cover
|
|
At the Seventh Conference on Retroviruses and Opportunistic Infections, researchers reported the discontinuation of highly active antiretroviral therapy (HAART) in four HIV patients followed by
therapeutic vaccination and interruption of therapy.
Two of the patients who were vaccinated with ALVAC 1452 and recombinant gp160 and then discontinued HAART had a delayed viral rebound and increases in cytotoxic T lymphocyte activity. The other
two patients experienced a rapid viral rebound. The findings support the idea that successful HAART therapy followed by therapeutic vaccination can help immune responses delay HIV rebound.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
